BUSINESS
Japan pharma: post-quake analysis
Recent expansion into international markets and the outsourcing of production to networks of external vendors spared Japanese drugmakers from major earthquake-inflicted disaster
- Five ways to get it right in India
- Asian-flavoured pharma deals
- Asia life science-focused VC firms
- M&A Watch Asia
CLINICAL TRIALS
CMIC shows first-mover advantage in Japan's CRO market
Smart service providers align their business models with the evolving regulatory environment and the changing needs of their pharmaceutical customers. For CMIC, one of Japan's earliest CROs, and now its biggest, future growth will come from tapping other dynamic Asian clinical trials markets
More Clinical TrialsPOLICY & REGULATION
Two years on, China's healthcare reforms a mixed bag for industry
China’s sweeping reforms are fundamentally changing the face of healthcare provision and delivery, creating new business opportunities for domestic players and multinationals alike
- EU and ASEAN free trade: win-win partnerships?
- Is India's new trustbuster up to scratch?
- Australia and New Zealand revive the ANZTPA
VIEW FROM ASIA
Flexibility key to riding Asia's giants
On the surface there are a number of similarities between China and India large, mostly rural populations, an emerging middle class demanding better healthcare, and fast-growing pharma markets driven by the "Westernisation" of diseases. While both countries offer robust domestic markets, Indian firms appear to have a head-start in terms of establishing an overseas focus. By contrast, Chinese firms have been hit over the years with many annual and biannual price cuts which have reduced their profitability and their ability to grow abroad. Read more...
Scrip Asia 100
C-SUITE VIEWS
Merck tailors emerging market strategies
By 2013, Merck & Co wants the leading emerging markets to account for a quarter of its revenues, representing a 50% hike from 2010. Dr Merv Turner, Merck's chief strategy officer, explains how the company, currently ranked fifth in emerging markets, plans to hit such an ambitious target.
Listen to Merv Turner in conversation with Scrip's Mike Ward |
Download the Merv Turner podcast in mp3 format Right click and select 'Save target/link as' from the menu |
COMPANIES
Proof of concept that China can innovate
Collaborations with big pharma, healthy venture investments and a robust pipeline make Shanghai-based Hutchison MediPharma a blueprint for Asian bioventures. CEO Dr Samantha Du talks about deals, drug development and doing business in China
Scrip is the single source for all pharmaceutical business intelligence.
Strengthen your commercial knowledge with full news and analysis. Sign up for a free 5-day trial now>
Latest news from scripnews.com
SPONSORS
|
|
|
|
|
|